Reclast (Zoledronic Acid): Once-Yearly IV Infusion for Osteoporosis

Reclast (zoledronic acid) is a bisphosphonate medication for osteoporosis given as a single IV infusion once a year. It works by binding to bone mineral and inhibiting osteoclasts — the cells that break down bone — for up to a full year from a single dose. It is the most potent bisphosphonate available and is also used in patients who have failed or cannot tolerate oral bisphosphonates like Fosamax.

Reclast is given as a 15-minute intravenous (IV) infusion, typically in a clinic or infusion center once a year. No fasting is required, and there is no need to remain upright afterward — a major advantage over oral bisphosphonates. It is important to be well-hydrated before the infusion to reduce the risk of kidney irritation and flu-like symptoms.

The most common side effect is an 'acute phase reaction' — flu-like symptoms including fever, muscle aches, fatigue, and joint pain — occurring 24–72 hours after the first infusion in about 30% of patients. This typically resolves within 3 days and is much less common with subsequent annual doses. Taking acetaminophen or ibuprofen before and for 24–48 hours after the infusion significantly reduces these symptoms. Serious but rare risks include osteonecrosis of the jaw and atypical femur fractures (both rare with appropriate use and monitoring).

Reclast should be used with caution and is contraindicated in patients with eGFR below 35 mL/min. Adequate hydration before the infusion is critical to protect kidney function. If you have kidney disease, your endocrinologist will review your kidney function before each annual infusion. Prolia is often preferred in patients with low eGFR.

Reclast is given once yearly. Most guidelines recommend reassessing after 3–6 years of treatment. For lower-risk patients, a 'bisphosphonate holiday' (temporary pause) may be considered after 5 years of oral bisphosphonates or 3 years of Reclast. Higher-risk patients — those with a history of hip or vertebral fracture — should generally continue treatment. Your endocrinologist will guide this decision based on your DEXA results and fracture history.

The main advantage is convenience and compliance. A once-yearly infusion eliminates the challenge of remembering weekly oral medication, maintaining strict fasting requirements, and avoiding lying down. Studies show that yearly Reclast produces similar or better fracture reduction than weekly Fosamax, and infusion-based delivery may achieve more consistent drug levels. For patients who forget pills or have GI side effects from oral bisphosphonates, Reclast is an excellent alternative.